Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07115485 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: HLX43 DOSE 1
DRUG: HLX43 DOSE 2
DRUG: HLX43 DOSE 3

Sponsor

Shanghai Henlius Biotech